It's almost time Fools. The American Society of Clinical Oncology annual meeting, the most important cancer meeting of the year, starts tomorrow.
Abstracts for the meeting came out a few weeks ago, giving investors a preview of what to expect during the five-day-long conference.
A lung cancer winner
Lung cancer is notoriously hard to treat. Bayer and Onyx Pharmaceuticals' Nexavar just joined the graveyard last week. But a compound from Array BioPharma
In a phase 2 trial, selumetinib combined with Sanofi's Taxotere increased overall survival by 4.2 months compared with Taxotere alone. That's insanely impressive, given that it nearly doubled the survival of the control arm. The data aren't statistically significant, but that's OK for an interim look at a phase 2 trial. The data clearly shows the drug is working.
Expanding the market
Back from the dead?
But ridaforolimus doesn't look quite dead yet. In a smaller lung cancer trial than Array's, ridaforolimus produced an overall survival of 18 months compared to five months for the placebo group. That looks outstanding, but I would expect the gap to narrow a little as more patients read out. The difference in progression free survival was only four months versus two months, favoring ridaforolimus.
ARIAD also has a leukemia drug called ponatinib, which looks interesting and worth keeping an eye on.
Safety, safety, safety
The cat's out of the bag on AVEO Oncology and Astellas Pharma's tivozanib, which beat Nexavar in a head-to-head trial in kidney cancer. Since Pfizer's
Going for hit two
Onyx has been a one-hit wonder for years, but it looks like it'll be able to expand beyond Nexavar with its multiple myeloma drug carfilzomib. The drug will face an advisory panel on June 20, but with so many oncology doctors running around the meeting, investors should get a good idea of how that meeting will go from the presentation of its pivotal phase 2 trial for patients who failed Takeda's Velcade or Celgene's Thalomid or Revlimid.
More data to come?
The deadline for submitting abstracts for the meeting was Feb. 1, so the data we have right now from the abstracts is only current though then. For ongoing trials, companies can, and usually do, present the currently available data.
And even for trials that have already completed, the presentations are important because not all the data is included in the abstracts. Sometimes the finer points, like AVEO's safety data, are just as important as the top-line data.
Check back next week for the Fool's take on the most interesting presentations at ASCO.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Access your report -- it's totally free.
Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
3 Dividend Stocks With Better Yields Than PepsiCo
The soft-drink giant offers a solid quarterly dividend, but these three promising businesses will pay you even more to own their shares.
What Happened in the Stock Market Today
On a day stocks bounced up and down, shares of Energizer Holdings rose on acquisition news, and Merck reported positive results in a lung cancer trial.
These 3 Dividend Giants Are Safer Than You Think
Concerns about these stocks and their dividends are overblown.